

# Mario Rizzetto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8476119/mario-rizzetto-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

3,313  
citations

32  
h-index

55  
g-index

139  
ext. papers

3,906  
ext. citations

6.9  
avg, IF

5.58  
L-index

#	Paper	IF	Citations
123	Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report.. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
122	The changing context of hepatitis D. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1200-1211	13.4	24
121	The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. <i>Liver International</i> , <b>2021</b> , 41, 16-19	7.9	2
120	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 583-605	6.1	4
119	Endpoints and New Options for Treatment of Chronic Hepatitis D. <i>Hepatology</i> , <b>2021</b> , 74, 3479-3485	11.2	4
118	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , <b>2021</b> , 33, 183-187	13	0
117	Hepatitis D virus in Uzbekistan. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 238-240	18.8	1
116	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 96, 114985	2.9	7
115	The Discovery of the Hepatitis D Virus: Three Princes of Serendip and the Recognition of Autoantibodies to Liver-Kidney Microsomes. <i>Clinical Liver Disease</i> , <b>2020</b> , 16, 1-11	2.2	2
114	The medical impact of hepatitis D virus infection in Uzbekistan. <i>Liver International</i> , <b>2019</b> , 39, 2077-2081	7.9	8
113	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , <b>2019</b> , 110, 401-409	2.2	9
112	Hepatitis D Virus <b>2019</b> , 135-148		3
111	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 793-795	13.4	2
110	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1008-1015	13.4	40
109	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B eAntigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 118-125	3.4	11
108	Targeting Hepatitis D. <i>Seminars in Liver Disease</i> , <b>2018</b> , 38, 66-72	7.3	14
107	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 53, 79-84	3.9	52

106	Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8 T Cells. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	14
105	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 301-307	13.4	69
104	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 320-327	19.7	57
103	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , <b>2018</b> , 38, 842-850	7.9	41
102	Investigational drugs in development for Hepatitis D. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 999-1005	5.9	6
101	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon- $\alpha$ . <i>Hepatology Research</i> , <b>2017</b> , 47, 747-754	5.1	17
100	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. <i>Panminerva Medica</i> , <b>2017</b> , 59, 283-289	2	26
99	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 375-381	3.1	
98	Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. <i>BMJ Open Gastroenterology</i> , <b>2016</b> , 3, e000119	3.9	5
97	Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , <b>2016</b> , 46, E130-5	5.1	38
96	The adventure of delta. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 135-40	7.9	45
95	Hepatitis D <b>2016</b> , 1409-1423		
94	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2016</b> , 63, 107-16	11.2	42
93	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 55-61	3.3	16
92	Chronic Hepatitis D; at a Standstill?. <i>Digestive Diseases</i> , <b>2016</b> , 34, 303-7	3.2	8
91	Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites: Relationship and effect on survival. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 702-8	3.3	4
90	Hepatitis D Virus: Introduction and Epidemiology. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2015</b> , 5, a021576	5.4	86
89	The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 1119-1120	25.5	10

88	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 405-10	3.3	6
87	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 41-7	13.4	54
86	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2015</b> , 69, 63-9	7.5	12
85	Antiplatelet and anticoagulant drugs management before gastrointestinal endoscopy: do clinicians adhere to current guidelines?. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 45-9	3.3	7
84	Endoscopic ultrasound in common bile duct dilatation with normal liver enzymes. <i>World Journal of Gastrointestinal Endoscopy</i> , <b>2015</b> , 7, 799-805	2.2	11
83	Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 826-32	3.3	11
82	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , <b>2014</b> , 109, 7-14	10.8	12
81	Prospective randomized trial: endoscopic follow up 3 vs 6 months after esophageal variceal eradication by band ligation in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 674-9	3.9	5
80	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 98, 271-8	3.5	21
79	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: a randomised trial. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 803-7	3.3	11
78	Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays. <i>Journal of Clinical Virology</i> , <b>2014</b> , 60, 341-6	14.5	19
77	Chronic hepatitis D at a standstill: where do we go from here?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 68-71	24.2	35
76	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. <i>Gastroenterology</i> , <b>2014</b> , 146, 744-753.e3	13.3	37
75	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 13146-52	5.6	19
74	Hepatitis delta: the rediscovery. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 475-87	4.6	38
73	Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. <i>Hepatology International</i> , <b>2013</b> , 7, 1075-83	8.8	14
72	Current management of delta hepatitis. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 195-7	7.9	14
71	Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. <i>Hepatitis Monthly</i> , <b>2013</b> , 13, e8210	1.8	34

70	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1254-8	13.4	29
69	Treatment of hepatitis B virus cirrhosis. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 309-11	1.8	2
68	Epidemiology of hepatitis D. <i>Seminars in Liver Disease</i> , <b>2012</b> , 32, 211-9	7.3	74
67	Hepatitis D(delta). <i>Seminars in Liver Disease</i> , <b>2012</b> , 32, 193-4	7.3	1
66	HDV: thirty years later. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43 Suppl 1, S15-8	3.3	17
65	Hepatitis D: clinical features and therapy. <i>Digestive Diseases</i> , <b>2010</b> , 28, 139-43	3.2	21
64	Outcome of chronic delta hepatitis in Italy: a long-term cohort study. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 834-40	13.4	89
63	Delta Hepatitis: Forgotten, but Not Gone. <i>Current Hepatitis Reports</i> , <b>2010</b> , 9, 239-242		1
62	Hepatitis D: the comeback?. <i>Liver International</i> , <b>2009</b> , 29 Suppl 1, 140-2	7.9	18
61	Hepatitis D: thirty years after. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1043-50	13.4	174
60	Chronic HBV-related liver disease. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 72-84	16.7	38
59	Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 173-9	13.4	70
58	Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S168-71	13.4	13
57	Progress in the prevention and control of viral hepatitis type B: closing remarks. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 463-6	19.7	5
56	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2002</b> , 66, 435-45	19.7	40
55	Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. <i>Liver Transplantation</i> , <b>2002</b> , 8, 630-5	4.5	27
54	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B <b>2002</b> , 66, 435		4
53	Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2002</b> , 66, 435-5	19.7	7

52	Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. <i>Lipids</i> , <b>2001</b> , 36, 1117-24	1.6	68
51	Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. <i>Hepatology</i> , <b>2000</b> , 32, 824-7	11.2	182
50	Posttransplantation prevention and treatment of recurrent hepatitis B. <i>Liver Transplantation</i> , <b>2000</b> , 6, S47-51	4.5	12
49	Changing pattern of chronic hepatitis D in Southern Europe. <i>Gastroenterology</i> , <b>1999</b> , 117, 161-6	13.3	97
48	Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. <i>Hepatology</i> , <b>1998</b> , 27, 873-6	11.2	31
47	The epidemiology of hepatitis delta infection in Italy. Promoting Group. <i>Journal of Hepatology</i> , <b>1992</b> , 15, 211-5	13.4	48
46	Patterns of hepatitis delta virus reinfection and disease in liver transplantation. <i>Gastroenterology</i> , <b>1991</b> , 101, 1649-55	13.3	125
45	A randomized controlled trial of a 12-month course of recombinant human interferon- $\beta$ in chronic delta (type D) hepatitis: A multicenter Italian study. <i>Hepatology</i> , <b>1991</b> , 13, 1052-1056	11.2	108
44	Management of hepatitis D virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1991</b> , 6 Suppl 1, 23-5	4	6
43	A randomized controlled trial of a 12-month course of recombinant human interferon- $\beta$ in chronic delta (type D) hepatitis: A multicenter Italian study <b>1991</b> , 13, 1052		10
42	A histological study of hepatitis delta virus liver disease. <i>Hepatology</i> , <b>1986</b> , 6, 1303-7	11.2	70
41	Familiar clustering and spreading of hepatitis delta virus infection. <i>Journal of Hepatology</i> , <b>1985</b> , 1, 221-6	13.4	37
40	Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. <i>Lancet, The</i> , <b>1985</b> , 2, 356-8	40	57
39	The delta agent. <i>Hepatology</i> , <b>1983</b> , 3, 729-37	11.2	319
38	Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. <i>American Journal of Epidemiology</i> , <b>1983</b> , 117, 223-9	3.8	100
37	Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. <i>Annals of Internal Medicine</i> , <b>1983</b> , 98, 437-41	8	272
36	Normal lymphocyte interferon production in adult HBsAg-positive chronic active liver disease. <i>Journal of Medical Virology</i> , <b>1979</b> , 4, 43-50	19.7	2
35	Pathogenesis, Diagnosis and Treatment of Ascites in Cirrhosis	666-710	1

34	Imaging of the Liver500-548	
33	Drug-Induced Liver Injury1209-1268	6
32	Liver Sinusoidal Endothelial Cells29-35	
31	Macroscopic Anatomy of the Liver1-8	
30	Liver Injury in Man Ascribed to Non-Drug Chemicals and Natural Toxins2105-2121	
29	Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis1193-1208	2
28	Development of the Liver Interactome: Mapping the Regulatory Networks2088-2095	0
27	Liver and Biliary Tract Histology9-19	1
26	The Liver in Lung Diseases1616-1621	0
25	The Liver in Urogenital Diseases1653-1661	0
24	Human Immunodeficiency Virus and the Liver974-987	0
23	Total Parenteral Nutrition-Related Liver Disease1634-1641	0
22	Haematological Abnormalities in Liver Disease1767-1779	0
21	Haemostasis in Liver Disease1780-1797	0
20	Prescribing Drugs in Liver Disease1912-1921	1
19	The Evolution of Cirrhosis581-589	1
18	Biliary Epithelial Cells52-57	
17	Intrahepatic Cholestasis1479-1500	1

16	Fungal Infections Affecting the Liver1011-1019	1
15	Pathology of Alcoholic Liver Disease1148-1156	1
14	Alcoholic Liver Disease: Natural History, Diagnosis, Clinical Features, Evaluation, Prognosis and Management1157-1178	
13	Obstruction of the Portal Vein1395-1402	1
12	Malignant Tumours1437-1463	1
11	Ultrastructure of the Hepatocyte20-28	1
10	Kupffer Cells36-42	2
9	The Liver in Cardiovascular Disease1607-1615	1
8	The Effect of Gastrointestinal Diseases on the Liver and Biliary Tract1622-1633	1
7	The Effect of Haematological and Lymphatic Diseases on the Liver1662-1670	1
6	The Liver in Graft-vs.-Host Disease1671-1679	1
5	Musculoskeletal Diseases and the Liver1694-1701	1
4	Biochemical Investigations in the Management of Liver Disease451-467	4
3	Hepatic Removal Kinetics: Importance for Quantitative Measurements of Liver Function468-478	4
2	Positron Emission Tomography of the Liver561-566	2
1	Clinical and Diagnostic Aspects of Cirrhosis604-619	5